Effect of Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Rouen, France, 76031
- CHU-Rouen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Premature neonates aged 30-33 weeks of gestational age
- Aged at least 2 days and no more than 10 days
- Free of acute illness
- Written informed consent is obtained from the parent prior to enrolment.
Exclusion Criteria:
- Premature infants with respiratory (fraction of inspired oxygen [FiO2] > 30%), or cardiovascular, liver, intestinal or acute diseases
- Premature infants with congenital syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
gastric emptying
Time Frame: at day 0, day 1, day 7 and day 14 of enteral nutrition enriched by glutamine or isonitrogenous product
|
at day 0, day 1, day 7 and day 14 of enteral nutrition enriched by glutamine or isonitrogenous product
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
intestinal transit
Time Frame: at day 1 and day 14 of enteral nutrition enriched by glutamine or isonitrogenous product
|
at day 1 and day 14 of enteral nutrition enriched by glutamine or isonitrogenous product
|
|
date and duration of arrest of nutrition if necessary
|
|
|
age of total enteral nutrition
|
|
|
age at the end of hospitalization
|
|
|
variation of cholescystokinin and gastrin postprandial concentration
Time Frame: at day 0 and day 14
|
at day 0 and day 14
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anne Mercier, MD, CHU Rouen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Obstetric Labor, Premature
- Obstetric Labor Complications
- Pregnancy Complications
- Premature Birth
- Amino Acids, Peptides, and Proteins
- Amino Acids
- Amino Acids, Basic
- Amino Acids, Diamino
- Amino Acids, Neutral
- Glutamine
- alanylglutamine
Other Study ID Numbers
Other Study ID Numbers
- 2000/111/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.